[64Cu]Cu-FAP-NOX:一种N-草酰基修饰的环肽用于具有灵活成像时间窗的FAP PET显像
本研究开发了新型64Cu标记环肽[64Cu]Cu-FAP-NOX靶向成纤维细胞活化蛋白(FAP),在A549.hFAP细胞和HEK-293T.hFAP荷瘤小鼠中与[64Cu]Cu-FAPI-04、[68Ga]Ga-FAP-2286等示踪剂比较,并在1例肺癌患者中完成首次人体研究。结果显示该示踪剂细胞摄取快、内化高、外排低,肿瘤与正常组织比值随时间显著升高且最高,患者原发灶摄取与FDG PET相当、胸膜转移摄取更高。
要点
- 在A549.hFAP细胞中,[64Cu]Cu-FAP-NOX较[64Cu]Cu-FAPI-04细胞摄取和内化更快更高,外排更低。
- 在HEK-293T.hFAP荷瘤小鼠中,[64Cu]Cu-FAP-NOX肿瘤摄取更强、洗脱更慢,肿瘤与正常组织比值随时间显著升高且最高。
- 1例肺癌患者中,[64Cu]Cu-FAP-NOX PET原发灶与FDG PET相当,胸膜转移摄取更高,与FAP免疫组化高表达一致。
核心结论
- [64Cu]Cu-FAP-NOX是有前景的FAP靶向示踪剂,具有高度灵活的成像时间窗,临床前评价和1例患者应用均支持这一点。
- [64Cu]Cu-FAP-NOX在FAP PET显像中显示增强的图像对比度和有利的药代动力学特性,值得转化为大型队列研究。
研究设计与样本
- 构建N-草酰基修饰尾链的新型环肽并偶联NOTA用于64Cu标记。
- 在A549.hFAP细胞中进行生化和细胞实验。
- 在HEK-293T.hFAP荷瘤小鼠中,用micro-PET比较[64Cu]Cu-FAP-NOX与[64Cu]Cu-FAPI-04、[68Ga]Ga-FAP-2286及三种不同NOTA偶联物的性能。
- 进行离体生物分布研究以确认FAP特异性并验证PET数据。
- 在1例肺癌患者中开展首次人体研究。
主要发现
- 与[64Cu]Cu-FAPI-04相比,[64Cu]Cu-FAP-NOX在A549.hFAP细胞中细胞摄取和内化速率更快更高,但细胞外排速率更低。
- 所有六种放射性示踪剂在注射后4小时内均被肿瘤快速摄取。
- [64Cu]Cu-FAP-NOX肿瘤积聚更强,且从靶点洗脱更慢。
- 肿瘤与正常组织(包括肾脏和肌肉)的比值随时间显著升高,[64Cu]Cu-FAP-NOX在所有示踪剂中达到最高比值。
- 患者中,[64Cu]Cu-FAP-NOX PET在原发恶性病灶显示与FDG PET相当的结果,同时在胸膜转移中显示更高摄取,经免疫组化证实与FAP表达升高一致。
局限性
- 首次人体研究仅在一例肺癌患者中进行。
- 作者指出值得转化为大型队列研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of the present study was to develop a novel 64Cu-labeled cyclic peptide ([64Cu]Cu-FAP-NOX) that targets fibroblast activation protein (FAP) and may offer advantages in terms of image contrast, imaging time window, and low uptake in normal tissues. METHODS: The novel cyclic peptide featuring with a N-oxalyl modified tail was constructed and conjugated to NOTA for 64Cu labeling. Biochemical and cellular assays were performed with A549.hFAP cells. The performance of [64Cu]Cu-FAP-NOX was compared to that of two established tracers ([64Cu]Cu-FAPI-04 and [68Ga]Ga-FAP-2286) and three different NOTA-conjugates in HEK-293T.hFAP xenograft mice using micro-PET imaging. Ex vivo biodistribution studies were performed to confirm the FAP specificity and to validate the PET data. Furthermore, a first-in-human study of this novel tracer was conducted on one patient with lung cancer. RESULTS: Compared to [64Cu]Cu-FAPI-04, [64Cu]Cu-FAP-NOX demonstrated faster and higher rates of cellular uptake and internalization in A549.hFAP cells, but lower rates of cellular efflux. All six radiotracers were rapidly taken up by the tumor within the first 4 h post-injection. However, [64Cu]Cu-FAP-NOX had more intense tumor accumulation and slower washout from the target. The ratios of the tumor to normal tissue (including kidneys and muscles) increased significantly over time, with [64Cu]Cu-FAP-NOX reaching the highest ratio among all tracers. In the patient, [64Cu]Cu-FAP-NOX PET showed a comparable result to FDG PET in the primary malignant lesion while exhibiting higher uptake in pleural metastases, consistent with elevated FAP expression as confirmed by immunohistochemistry. CONCLUSION: [64Cu]Cu-FAP-NOX is a promising FAP-targeted tracer with a highly flexible imaging time window, as evidenced by preclinical evaluation encompassing biodistribution and micro-PET studies, along with a successful patient application. Furthermore, [64Cu]Cu-FAP-NOX showed enhanced image contrast and favorable pharmacokinetic properties for FAP PET imaging, warranting translation into large cohort studies.
引用
- Liu S, Zhong J, Zhang Z, et al. [64Cu]Cu-FAP-NOX, a N-oxalyl modified cyclic peptide for FAP PET imaging with a flexible imaging time window. Eur J Nucl Med Mol Imaging. 2024. PMID: 38910166. doi:10.1007/s00259-024-06807-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。